Fierce Pharma

Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the tolerability of the two COVID vaccines.

Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC
Hosted on MSN

Moderna's combo Covid and flu mRNA shot outperforms current vaccines in large trial

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the results of a phase 3 clinical trial published Wednesday in the Journal of the American Medical Association. The vaccine uses the same ...
Yahoo

FDA refuses to review Moderna’s application for mRNA flu vaccine, company says

Add Yahoo as a preferred source to see more of our stories on Google. Moderna said the FDA's refusal was inconsistent with previous feedback from the agency. - Graham Hughes/Bloomberg/Getty Images The US Food and Drug Administration has refused to accept ...
MedCity News

Moderna Says FDA Refusal to Review mRNA Flu Vaccine Contradicts Federal Rules, Prior Guidance

Moderna’s messenger RNA influenza vaccine succeeded in two pivotal clinical trials, but the Food and Drug Administration is refusing to even review the application seeking regulatory approval, telling the company that the comparator in the studies — an ...